Electrocardiographic changes in QTc interval and other parameters associated with osimertinib therapy
{{output}}
Introduction: Osimertinib, a third-generation EGFR-TKI, is approved for the first-line treatment of EGFR-mutated advanced NSCLC and for T790M-positive NSCLC after progression on previous EGFR-TKI therapy. Osimertinib is associate... ...
